Halozyme Therapeutics, Inc. (HALO) is a publicly traded Healthcare sector company. As of September 12, 2026, HALO trades at $106.32 with a market cap of $12.14B and a P/E ratio of 30.07. HALO moved +0.21% today. Year to date, HALO is +52.47%; over the trailing twelve months it is +38.27%. Its 52-week range spans $47.50 to $111.15. Analyst consensus is buy with an average price target of $97.14. Rallies surfaces HALO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for HALO shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $106.32 |
| Market Cap | $12.14B |
| P/E Ratio | 30.07 |
| EPS | $3.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $111.15 |
| 52-Week Low | $47.50 |
| Volume | 746.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.66B |
| Net Income | $413.60M |
| Gross Margin | 82.42% |
7 analysts cover HALO: 0 strong buy, 5 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $97.14.